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services. For the 2012 sample, it is possible that MCBS beneficiaries might have used 
preventive screening within the previous year which resulted in underutilization 
of those services in 2012. Further research should extend the period of analysis to 
investigate whether observed decrease remains unchanged over time.
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Objectives: Colorectal cancer (CRC) is largely preventable using screening to detect 
and remove adenomatous polyps during flexible sigmoidoscopy (FS) and colonos-
copy, or to identify early-stage cancers with fecal occult blood testing (FOBT) and 
fecal immunochemical testing (FIT). Despite the proven efficacy of CRC screen-
ing (CRCS), screening rates remain relatively low. Patient’s psychological barriers 
seem to affect participation in CRCS. We conducted a comprehensive review of the 
literature to identify psychological barriers associated with CRCS. MethOds: We 
conducted a systematic review of studies reporting on psychological factors and 
colorectal cancer screening from 2004 to 2014 using MEDLINE/PubMed and Google 
Scholar. Limiting the search to the English language reports, the search strategy 
involved combining (a) colorectal cancer screening-related key words (eg, ‘‘cancer,’’ 
‘‘screening,’’ ‘‘adherence,’’ ‘‘colonoscopy,’’ ‘‘sigmoidoscopy,’’ ‘‘chemotherapy’’) and 
(b) words pertaining to or synonymous with fear (eg, ‘‘fear,’’ ‘‘anxiety,’’ ‘‘embarrass-
ment,’’ ‘‘belief). Results: Of the 17 articles identified, 11 explored general barri-
ers among the U.S. population, while the other 6 examined specific barriers such 
as fear, disgust, perceptions, attitudes, knowledge, and medical mistrust. Six of 
the studies were qualitative studies, 4 were quantitative study, 3 used a mixed 
methods approach and 4 were reviews. Sample sizes varied from 23-55 subjects in 
the qualitative studies; and 151-454 subjects in the quantitative studies. Common 
perceived barriers included mistrust of the healthcare system, embarrassment of 
being undressed in front of a provider, the nature of the screening exam itself, 
fear of being a burden to the family, and fatalism. cOnclusiOns: The results of 
this study demonstrate that psychological factors such as fear of the test itself, of 
cancer diagnosis, of burdening family members, and embarrassment play a role in 
determining whether patients would opt for CRCS. In order to improve the quality 
of care and successfully increase screening rates for CRC, overcoming these barriers 
is of utmost importance.
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Objectives: ST-segment elevation myocardial infarction (STEMI) is a leading cause 
of global morbidity and mortality, comprising 25-40% of MI presentations, with vary-
ing outcomes. 5-6% of patients die before leaving hospital, and 7-18% of discharged 
patients die within one year. In Romania, the annual mortality rate is 14.5% for admit-
ted patients. An Excel-based model was developed to assess the clinical and economic 
impact of different treatment strategies for STEMI patients in Romania. MethOds: 
This model uses data from the Romanian National Registry, Romanian Heart 
Foundation, and CC Iliescu Heart Institute to evaluate STEMI treatment scenarios 
based on disease awareness, timely hospital admissions, and treatment with PCI, 
versus alternative approaches such as thrombolytics or no reperfusion. 2009-2014 
outcomes were modeled year-over-year for sequential STEMI cohorts. Prospective 
outcomes through 2019 were modeled to calculate the value of continued invest-
ment in STEMI management. Model inputs included morbidity and mortality, labor 
productivity (measured by average wage), direct treatment costs, and disease burden 
(measured by disability-adjusted life-years and value of a statistical life). Outputs 
were calculated up to one year after initial STEMI event, and calculated separately 
for hospital-admitted and non-admitted populations, with the latter group divided 
by treatment pathway: PCI, thrombolytics, no reperfusion, or CABG. Results: From 
2009-2014, an investment of 20.8 million € in interventional cardiology and catheteri-
zation laboratories resulted in 2,197 lives saved, with cost savings of 21.6 million € 
from improved productivity. Prospective calculations through 2019 show an invest-
ment of 14.2 million € would result in 1,528 lives saved, with cost savings of 12.3 
million € . cOnclusiOns: From 2009-2014, Romanian healthcare expenditures to 
improve STEMI management strategies showed favorable clinical outcomes when 
more patients were managed with PCI. This mortality reduction suggests that con-
tinued national investment in STEMI management could further improve these rates, 
with greater cost savings achieved as a result.
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Objectives: Use of operating rooms (OR) in hospitals contributes significantly to the 
total cost of inpatient care. Autologous fat grafting (AFG) is a process of re-injecting 
a patient’s own fat to treat soft tissue defects in surgeries. The objective was to com-
pare the impact of a new AFG system, Revolve versus centrifugation on OR time and 
costs. MethOds: Data from literature, conference posters and surgeon survey (n= 30) 
were used. Cost of OR included staff wages and facility costs, and adjusted for inflation 
to 2014 USD. Mean time of completing AFG was estimated using rate and volume of fat 
injected reported in posters. Inputs required for projection such as mean number of 
AFG procedures per year for a hospital were obtained from survey. Per case incremen-
tal differences in OR cost for Revolve versus centrifugation was estimated by dividing 
volume of fat injected by rate of AFG and multiplying by OR cost prior to subtracting 
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Objectives: During 2013, Argentina (AR) suffered severe currency depreciation (above 
32%) and an annual inflation rate of 28%. Increases in imported medical devices’ 
prices (MDs) plus a weakened AR peso might have impacted their access. The objective 
of this research was to evaluate the impact of the 2013 Argentinian economic crisis in 
the healthcare (HC) sector and the access of imported medical devices. MethOds: 
Specific analysis to evaluate MDs’ cost in HC system (private payers and provid-
ers) was performed. Primary cost information was obtained and analyzed from the 
HC System and ADECRA (Argentinian Healthcare Private Providers Association). 
The information includes inflation-adjusted costs incurred by the provision of HC 
services (labor costs, medical and non-medical supplies, among others). From the 
manufacturer perspective, the mean percentage of MDs’ price increase and the sales 
amount of implantable joints prosthesis were considered and compared both in local 
currency and USD. Results: During 2013, the government allowed private payers 
to increase their fees by 25.5%. As a consequence, labor costs increased by 25.7%, 
affecting private payers and providers. For private healthcare providers, the cost to 
deliver care rose to 26.9%, whereas medical supplies and devices’ increase was 33.4%. 
Manufacturers raised their prices in 22%, while their sales rose in 28% in local cur-
rency, but only 5% in USD. cOnclusiOns: 2013 AR crisis affected the HC system. HC 
providers were mainly harmed as the result of price increases for MDs and supplies 
above the increase of its charges (services fees paid by the private system) and even 
below the ADECRA index (30%), which rose up to 200% compared to 2010. This repre-
sents a burden for payers, who had to absorb the price increase for the high cost of 
imported MDs in order to provide access to their population.
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Objectives: Abnormal uterine bleeding (AUB) is an increasingly frequent complaint 
of women visiting gynecologists’ offices. Uterine polyps, a common etiology, are 
traditionally removed in hospitals or ambulatory surgery centers (ASCs). A mini-
mally invasive hysteroscopic tissue removal system (TRUCLEAR™, Smith&Nephew) 
(HTRS) allows a shift of care site to office hysteroscopy (OH) with at least equal 
effectiveness plus increased patient convenience and safety. Current procedural 
coding does not allow offices to bill payers for HTRS so OH using HTRS loses money. 
HTRS advantages include patients are seen and treated during a single office visit, 
experience shorter procedure times, may avoid preliminary medications and gen-
eral anesthesia, and return to activity sooner. Patient and payer expenses could be 
reduced because overall costs of an office procedure are lower than those performed 
at hospitals or ASCs. MethOds: A mutually beneficial OH fee schedule for patients, 
offices and Blue Cross and Blue Shield of North Carolina (BCBS-NC) was determined. 
A global procedure fee estimated frequency of use of HTRS devices during OH. 
Immediate treatment also avoids the need to schedule treatment at a later time in 
the hospital or ASC. Avoiding the higher overhead charges of hospitals or ASCs for 
staff, operating and recovery rooms, plus general anesthesia allowed an increase in 
office reimbursement that offset HTRS cost while BCBS-NC realized a net reduction 
in overall payments. Results: A pilot program in October 2013 – November 2014 
increased allowable OH charges resulting in about $1500 higher payment for OH 
with estimated per procedure savings of as much as nearly $2000 for patients, from 
lower insurance deductibles, and $2800 to BCBS-NC compared to what they would 
have paid for the procedure in a hospital or ASC. cOnclusiOns: Shifting the site 
of service through payment modification allowed all stakeholders to benefit from 
improved financial and clinical outcomes.
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Objectives: During the last 30 years, a significant decrease in annual cancer inci-
dence rates was noted for colon and rectum, largely attributable to the utilization 
of colorectal screening services. This trend accelerated in recent years as these tests 
allow a doctor to localize and remove polyps of a precancerous character. The U.S. 
Preventive Services Task Force assigned grade A recommendation for colorectal 
screening beginning at age 50 and continuing until age 75 years. Moreover, the 
adoption of Patient Protection and Affordable Care Act resulted in an increased 
access to preventive services by eliminating all cost-sharing for colorectal screen-
ing among Medicare beneficiaries effective January 2011. The aim of this study is 
to investigate whether the new policy had an impact on the utilization of colorec-
tal screening among Medicare beneficiaries after January 2011. MethOds: This 
study used Medicare Current Beneficiary Survey (MCBS) Access to Care and Cost 
and Use files for years 2009 and 2011. Both community-dwelling and institution-
alized Medicare beneficiaries between 50 and 75 years of age were included into 
the study. Beneficiaries who underwent colectomy or who had colorectal cancer 
in any period included in the analysis were excluded. Results: Results show no 
statistical significance in colorectal screening utilization before and after January 
2011. The absolute numbers of patients who utilized preventative services in 2009 
(N= 782) and 2011 (N= 776) were comparable. However, fewer MCBS respondents uti-
lized colorectal screening in 2012. cOnclusiOns: Results for years 2009 and 2011 
suggest no impact of the policy changes on the utilization of colorectal screening 
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Objectives: A recent Premier study reported that despite hemostat use, uncon-
trolled bleeding is prevalent across surgery types (32%-68%).  Drawbacks of current 
hemostats include limitations with efficacy on first attempt and sub-optimal ease-
of-use; thus, better hemostats are needed.  A study was conducted to estimate the 
cost impact of a novel fibrin sealant patch (EVARREST™) versus standard of care 
(SoC) in soft tissue and hepatic surgical bleeding. MethOds: An economic model 
quantified 30-day cost impact of EVARREST from a U.S. hospital perspective.  Key 
resources, from four trials, included quantity of initial treatment, re-treatment, 
operating time, hospitalization, transfusion risk, amount transfused, and ventilator 
utilization.  SoC was composed of Surgicel (88% to 100% in soft tissue, 34% to 65% 
in hepatic tissue) and conventional methods (e.g., manual compression, thrombin). 
Transplant patients were excluded from analyses.  The surgical analysis included 
resources clinically related to the significant hemostasis benefit of EVARREST vs. 
control (i.e., initial and re-treatment, operating time, transfusion). A hospital analy-
sis included all resources collected. Published data on U.S. costs were applied to 
resource use. Sensitivity analyses were conducted on several variables including 
number of EVARREST products used. Results: The surgical base-case analysis 
predicted that EVARREST was cost saving vs. SoC by $59 per patient (sensitivity 
range: -$300 to $900).  The hospital analysis predicts further resource reduction 
with EVARREST with cost-savings of $2,789 per patient (sensitivity range: -$1,830 to 
-$3,338).  Results were most sensitive to the number of pads used.  Composite results 
were primarily driven by the large benefit achieved with EVARREST in severe soft-
tissue bleeding. cOnclusiOns: In problematic soft tissue and hepatic bleeding, 
EVARREST may result in important cost savings for hospitals, in addition to meeting 
an important unmet need. This analysis suggests EVARREST’s impact on hospital 
cost may depend on surgical bleeding type and number of pads used. Further study 
in additional populations may confirm findings.
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Objectives: The Harmonic® scalpel has demonstrated clinical and surgical ben-
efits as an effective and efficient alternative to traditional electrosurgery. However, 
ultrasonic devices incur higher device cost than electrosurgery. The aim of this study 
is to review the economic evidence comparing total procedural costs performed 
with ultrasonic devices to conventional techniques. MethOds: A comprehensive 
literature review was conducted to identify publications where ultrasonic energy 
devices were used in comparison with conventional surgical techniques for the 
period 2004-2014. No restriction on the surgical specialty was applied. Primary inclu-
sion criteria were: 1) randomized-controlled studies; 2) human studies; 3) total 
procedure cost was evaluated for economic impact. Articles were reviewed to collect 
direct and indirect cost information such as OR time, blood loss, hospital length of 
stay, resource and surgical consumables, as well as quality of life data. Results: For 
39 articles identified for full-text screening, 9 articles were evaluated based on the 
inclusion criteria. Therapeutic areas included breast, colon, and thyroid surgery. All 
economic studies considered total medical direct costs. Except for one article that 
showed ultrasonic devices to be more expensive and one that showed no economic 
difference, all other articles demonstrated that the higher cost of the Harmonic® 
device is offset by improved clinical outcomes and efficiency without an increase in 
surgical complications, especially in complicated procedures entailing considerable 
loss of blood or longer operative time. The average overall cost savings ranged from 
$85 to $400 USD per patient. Two studies estimated the incremental cost-effective 
ratio and both indicated the Harmonic® device to be superior compared to conven-
tional technique. cOnclusiOns: Ultrasonic devices shorten OR time and improve 
clinical outcomes in a variety of procedures investigated without an increase in 
complications, and thus can be considered as a cost effective alternative to con-
ventional surgical techniques.
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Objectives: Surgical bleeding remains prevalent and associated with substan-
tial burden. Such bleeding can be more difficult to manage in certain surgeries 
(e.g., liver). Hemostats with a fibrinogen, thrombin and patch component may be 
especially beneficial for problematic bleeding types; however, direct comparative 
data are limited. This study indirectly compared the hemostats EVARREST and 
TachoSil. MethOds: A structured literature search identified studies of fibrin 
sealants combined with use of a pad, patch, fleece or sponge, for surgical bleeding. 
The search was restricted to RCTs, 2000 onward, studies including standard of care 
(SoC) and time to hemostasis (TTH). EVARREST (4 trials) and TachoSil (6 trials) were 
identified as the comparators. Pair-wise meta-analyses were completed using a 
random-effects model for hemostat vs. SoC. An adjusted indirect comparison was 
conducted using Bucher methodology and ITC software (Wells, 2009) for calculat-
ing the mean difference (MD) in TTH between EVARREST and TachoSil with 95% 
confidence intervals (CI). Mean TTH was analysed as it is a well-accepted, recom-
mended measure. Typically, TTH measurements began at either 3 or 4 minutes. 
SoC was used as the ‘anchor’ to perform the indirect comparison and consisted 
of either conventional methods or topical hemostats. Indirect comparisons were 
completed for all surgery types and a liver surgery subgroup. Results: A total of 
894 patients were assessed. Across surgery types, the adjusted indirect comparison 
demonstrated EVARREST reduced mean TTH by 1.15 minutes compared to TachoSil 
(MD: -1.15; 95%CI: -3.29, 0.99), however, this difference was not statistically sig-
nificant. In the subgroup of liver surgical bleeding, EVARREST significantly reduced 
mean TTH by 2.73 minutes (MD: -2.73; 95%CI: -4.48, -0.981). cOnclusiOns: This 
analysis suggests EVARREST may provide better hemostasis than TachoSil, particu-
equipment costs ($495 list price of Revolve per use) and depreciated cost of centrifu-
gation ($10 per use). Annualized difference in costs was also estimated. Results: 
Base case assumed 100 AFGs per year (150mL of fat injected per case). Mean time to 
complete AFG was substantially faster using Revolve than centrifugation: 29.1 min-
utes versus 116.1 minutes (range: 25.1-32.0 versus 104.1-125.8 minutes, respectively). 
Mean volume of fat injected was greater for Revolve than centrifugation: 210.0mL 
versus 92.0mL (ranges: 179.0-241.2 versus 82.4-101.2mL, respectively). Consequently, 
rate of completing AFG was greater with Revolve than centrifugation: 5.2mL/min 
versus 1.3mL/min (range: 4.7-6.0 versus 1.2-1.4mL/min, respectively). Estimated 
cost savings for Revolve versus centrifugation was $2,075 per case and $207,476 per 
year. cOnclusiOns: As popularity of AFG increases, evaluating economic impact of 
AFG systems becomes essential. Based on current findings, Revolve system results in 
substantial OR time and cost savings compared to centrifugation.
PMD75
integrating Big Data to aSSeSS tHe eConoMiC iMPaCt of tHe 
iMPlantaBle CarDioverter DefiBrillator tHeraPy
Madotto F., Conti S., Chiodini V., Mantovani L.G., Fornari C., Cesana G.
University of Milano - Bicocca, Monza, Italy
Objectives: The main purpose of this study was to link clinical and administra-
tive healthcare databases in order to assess the economic impact of implantable 
cardioverter defibrillator (ICD) with or without cardiac resynchronization pacing 
(CRT-D) in Lombardy, the most populated Italian region providing universal health-
care coverage for about 10 million inhabitants. MethOds: Data were extracted 
from: i) data warehouse DENALI, that organizes healthcare administrative databases 
concerning all subjects covered by Lombardy Health System (HS); ii) national ICD 
database. After linking DENALI and clinical information extracted from the ICD 
database, we identified patients with ICD and followed them from the date of the 
first implant to 12/31/2010, recording hospitalizations, drugs and outpatient claims. 
Direct healthcare costs were analysed from the perspective of the HS. We estimated 
mean annual per-capita costs after the first ICD implant: overall and stratified by 
indication (primary and secondary prevention) or type of implanted device (sin-
gle-chamber, dual-chamber and CRT-D). Results: During the period 2003-2010, 
12,525 subjects underwent a first ICD implant. Mean annual per-capita cost during 
follow-up was € 6,086 (95%CI: 5,970-6,211): 72.7% due to hospitalizations (€ 4,422), 
15.7% to pharmacological therapies (€ 957) and 11.6% to outpatient services (€ 706). 
No difference was observed between the mean annual expenditure for primary 
(€ 6,179; 95%CI: 6,001-6,353) and secondary (€ 5,996; 95%CI: 5,821-6,185) prevention. 
As for the type of implanted device, patients with CRT-D cost more than those with 
single-chamber or dual-chamber: respectively € 6,592 (95%CI: 6,376-6,847), € 5,728 
(95%CI: 5,541-5,972) and € 5,932(95%CI: 5,717-6,117). The difference was attributable 
to hospitalization expenses. cOnclusiOns: ICD use is growing and it is important 
to assess the efficacy and the burden of this therapy, given its economic implica-
tions. The combined use of clinical information from national ICD database and big 
administrative data could overcome the limitation of both data sources, leading to 
an improvement in the monitoring of ICD therapy.
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Objectives: Diabetes (DM) is rapidly growing in China, affecting > 114 million peo-
ple. Lipohypertrophy (LH) is a known, preventable complication amongst insulin-
injecting DM patients. This study demonstrates the economic and patient burden of 
LH in China. MethOds: An observational study was conducted among 401 insulin-
injecting adult patients with DM from 4 cities, 2 with and 2 without pen needle 
reimbursement (PNR). Demographics, medical history, direct and indirect costs, 
insurance and PNR status were collected via patient survey, followed by HbA1c tests 
and physical exam to assess LH. Results: LH was present in 52.9% of participants. 
Patients were an average of 59.6 (SD= 11.5) years old and took insulin 5.6 (SD= 4.6) 
years, averaging 33.0 (SD= 18.4) U/day. HbA1c was 8.2% (1.8) and 7.7% (1.5), respec-
tively, in those with and without LH (p= 0.003). LH was associated with higher daily 
insulin dose (38.1U vs 27.1U, p< 0.001) and cost (RMB 8.2 vs 5.8, p< 0.001). Those with 
LH averaged 2.3 (2.2) nodes, had higher frequency of PN reuse (median 13.0 vs 7.5, 
p= 0.003), and greater total 6-month direct costs (RMB 5506.9 vs 5258.0, p= 0.037). 
With 8.4 million insulin injectors in China, the estimated excess annual direct cost 
of LH is RMB 2.2 billion ($360 million). Average pain scores (0-10) were higher if LH 
was present (2.7 vs. 2.0, p= 0.021), if ≥ 3 nodes were present (3.8 vs. 2.3, p< 0.001), and if 
PNs were not reimbursed (2.8 vs. 1.7, p< 0.001). Patient satisfaction decreased as pres-
ence, number, and size of LH nodes increased (all p< 0.05). cOnclusiOns: Adverse 
effects and implications of LH reach over half of insulin-injecting patients in China. 
Assessing for LH and providing patient education on proper injection technique, 
including injection site rotation and reducing PN reuse, should be incorporated into 
routine DM management. Doing so may decrease this preventable complication, 
which may lessen LH-related economic and patient burdens.
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